The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Aug. 04, 2020

Filed:

Dec. 05, 2016
Applicant:

The Regents of the University of California, Oakland, CA (US);

Inventors:

Yury Miller, La Jolla, CA (US);

Tony L. Yaksh, La Jolla, CA (US);

Assignee:
Attorneys:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
C07K 14/00 (2006.01); A61K 38/52 (2006.01); A61P 25/28 (2006.01); A61P 29/00 (2006.01); C12N 9/90 (2006.01); A61K 48/00 (2006.01); A61P 25/06 (2006.01); C07K 14/075 (2006.01); C07K 14/775 (2006.01); C12N 15/62 (2006.01);
U.S. Cl.
CPC ...
A61K 48/0058 (2013.01); A61K 38/52 (2013.01); A61P 25/06 (2018.01); A61P 25/28 (2018.01); A61P 29/00 (2018.01); C07K 14/00 (2013.01); C07K 14/075 (2013.01); C07K 14/775 (2013.01); C12N 9/90 (2013.01); C12N 15/62 (2013.01); C12N 2750/14143 (2013.01); C12Y 501/99006 (2015.07);
Abstract

In alternative embodiments, provided are methods for increasing levels of and/or upregulating the expression of ApoA-I Binding Protein (APOA1BP, AIBP, or AI-BP) to treat, ameliorate, prevent, reverse, decrease the severity or duration of: a neuropathic pain, including an inflammation-induced neuropathic pain, a nerve or CNS inflammation, a, a post nerve injury pain, a post-surgical pain, a chemotherapeutic-induced peripheral neuropathy (CIPN) (e.g., cisplatin-induced allodynia) a neurodegeneration or neurodegenerative disease or condition, a migraine, and/or a hyperalgesia. In alternative embodiments, provided are methods comprising administering formulations and pharmaceutical compositions comprising an APOA1BP polypeptide or protein that is a human or a mammalian APOA1BP, or an AIBP1 or an AIBP2, or a recombinant, peptidomimetic or a synthetic APOA1BP, or a bioisostere of an ApoA-I Binding Protein to treat, ameliorate prevent, reverse, decrease the severity of a neuropathic pain, a TLR4-mediated allodynia and/or a hyperalgesia.


Find Patent Forward Citations

Loading…